PhotoBiotics' OptiLink ADC Technology Features at the 10th Annual Congress on Recombinant Antibodies
London; May 2011:
PhotoBiotics Ltd, one of Britain's leading innovative targeted therapeutics companies, is presenting its unique proprietary OptiLink coupling technology at the 10th Annual Congress on Recombinant Antibodies Conference held this year in Barcelona, 24-26 May. OptiLink is a unique conjugation platform that enables multiple attachment of drugs (particularly for light-activated cancer therapeutics) to antibody fragments (eg. sc-Fvs). Counter-intuitively, OptiLink allows much larger drug loadings on smaller sc-Fvs than is achieved with much larger whole monoclonal antibodies.
Dr Mahendra Deonarain, PhotoBiotics' Chief Scientific Officer and Reader in Antibody Technology at Imperial College London, and presenting at the conference, says "Targeted photodynamic therapy (PDT) promises to combine the cosmetic benefits of laser therapy with the potency and specificity of antibody drug targeting. We have been developing optimised single-chain Fv frameworks specifically for accommodating covalently attached PDT drugs in a technology platform called "OptiLink". We show that scFv-based ADCs, activated by laser light can destroy tumours in a range of challenging animal models for ovarian and prostate cancer. We also suggest that the fluorescent properties of such ADCs can be used for imaging purposes.
Dr Deonarain continues, "Ultimately, PhotoBiotics' OptiLink platform will enable multiple loading of sc-Fv targeting moieties with both therapeutic and imaging agents. This will provide a pipeline of novel targeted 'see and treat' agents to improve efficacy and tolerability of cancer treatment, significantly shorten tumour treatment times, and improve patients' quality of life."
Notes For Editors
- 'Targeted photodynamic therapy with multiply loaded recombinant antibody fragments.' International Journal of Cancer 2008; 122: 1155-1163.
- 'Fluorescence characterisation of multiply-loaded anti-HER2 single-chain Fv-photosensitiser conjugates suitable for photodynamic therapy'. Photochemical and Photobiological. Sciences. 2007; 6: 933-939.
About PhotoBiotics
PhotoBiotics, a spin-out company from Imperial College London, is developing much improved targeted therapeutics. It has patented OptiLink, a unique yet simple conjugation platform that optimises the multiple attachment of drugs (e.g. cytotoxics and photosensitisers) to antibody fragments. These precisely targeted antibody-drug conjugates (ADCs) greatly increase efficacy and selectivity, with the prospect of developing breakthrough products (both therapeutic and diagnostic) across multiple indications. These products are particularly relevant in today's market, especially as the era of personalised medicines is becoming a reality. The application of PhotoBiotics' technology will lead to better, safer drugs. PhotoBiotics meets the key investment criteria of high potential value combined with relatively low risk. The Company operates an effective and capital-efficient semi-virtual business model, and is generating non-dilutive revenues from collaborations.
For more information please contact:
Dr Lionel R Milgrom, PhotoBiotics Ltd Press Office,
Tel: +44 (0)208 450 8760
Mob: +44 (0)7970 852156
Email: media@photobiotics.com
Press Releases
- PhotoBiotics' CSO presents at World ADC Summit in Frankfurt
Date : 01 March 2012 - PhotoBiotics' COO presents at major Antibody Drug Conjugate (ADC) conference in Barcelona
Date : 09 November 2011 - PhotoBiotics presents OptiLinkTM Antibody-drug conjugate (ADC) platform at World ADC Summit in San Francisco
Date : 25 October 2011 - PhotoBiotics Raises Further Funding for Antibody Drug Conjugates (ADCs)
Date : 11 October 2011 - PhotoBiotics' CSO hosts Antibody Drug Conjugate (ADC) event at Berlin Novel Protein Therapeutics Conference
Date : 27 September 2011 - A Conjugation Platform for the Targeted Delivery of Anticancer Agents
Date : 01 September 2011 - OptiLink ADC Technology Features at the 10th Annual Congress on Recombinant Antibodies
Date : 15 May 2011 - PhotoBiotics Announces Collaboration with Major Pharma Company
Date : 7 December 2010 - PhotoBiotics’ approach to Targeted Magnetic Resonance Imaging receives award from the National Institute for Health Research
Date : 6 September 2010 - Location! Location! Location! - PhotoBiotics' Key to Successful PDT
Date : 31 July 2010 - US patent granted to PhotoBiotics for new targeted cancer therapy
Date : 1 April 2010 - Targeted Photodynamic Therapy in Corfu and Wroclaw 2009
Date : 22 June 2009 - American Chemical Society Hosts Targeted Photodynamic Therapy at Salt Lake City
Date : 10 April 2009 - Patent for targeted photodynamic therapy (t-PDT) gets green light Down Under
Date : 7 October 2008 - Targeted Photodynamic Therapy (t-PDT) to light up Brixen / Bressanone Symposium
Date : 18 September 2008 - Novel Targeted Cancer Therapy on show at Dubrovnik
Date : 24 March 2008 - New targeted anti-cancer therapy lights up investors
Date : 29 January 2008 - Light-activated anti-cancer drugs on target
Date : 29 November 2007